These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
16. Lambert-Eaton myasthenic syndrome: search for alternative autoimmune targets and possible compensatory mechanisms based on presynaptic calcium homeostasis. Takamori M J Neuroimmunol; 2008 Sep; 201-202():145-52. PubMed ID: 18653248 [TBL] [Abstract][Full Text] [Related]
17. GRP78 antibodies damage the blood-brain barrier and relate to cerebellar degeneration in Lambert-Eaton myasthenic syndrome. Shimizu F; Takeshita Y; Sano Y; Hamamoto Y; Shiraishi H; Sato T; Yoshimura S; Maeda T; Fujikawa S; Nishihara H; Kitanosono H; Tsujino A; Motomura M; Kanda T Brain; 2019 Aug; 142(8):2253-2264. PubMed ID: 31236596 [TBL] [Abstract][Full Text] [Related]
18. [Favourable outcome after treatment with rituximab in a case of seronegative non-paraneoplastic Lambert-Eaton myasthenic syndrome]. Boutin E; Rey C; Romeu M; Pouget J; Franques J Rev Med Interne; 2013 Aug; 34(8):493-6. PubMed ID: 23759215 [TBL] [Abstract][Full Text] [Related]
19. Lambert-Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies. Titulaer MJ; Lang B; Verschuuren JJ Lancet Neurol; 2011 Dec; 10(12):1098-107. PubMed ID: 22094130 [TBL] [Abstract][Full Text] [Related]